Collegium Pharmaceutical, Inc. announced that effective May 24, 2024, Joe Ciaffoni will step down as Chief Executive Officer (CEO) of the Company. Mr. Ciaffoni will serve as a member of the Board of Directors of the Company until the upcoming 2024 Annual Meeting of Shareholders and will not stand for re-election at the meeting. To ensure a seamless transition, Michael Heffernan, founder, former CEO and Chairman of the Board will serve as Interim CEO until a new CEO is appointed by the Board of Directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.67 USD | -0.03% |
|
-0.47% | +2.89% |
06-13 | Collegium Pharmaceutical Says Nucynta Gets FDA Pediatric Exclusivity | MT |
06-13 | Collegium Pharmaceutical, Inc. Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.89% | 1.04B | |
+52.70% | 801B | |
+41.58% | 631B | |
-4.86% | 359B | |
+21.96% | 337B | |
+11.47% | 305B | |
+17.72% | 245B | |
+4.46% | 231B | |
+13.13% | 219B | |
+10.46% | 171B |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Collegium Announces CEO Transition